Tevogen Inc. (TVGN) earnings
TVGN earnings moved a median of -1.80% by the close. Quarterly and annual TVGN reports and results, each read against the price at its own news timestamp. Back to the TVGN overview →
21 measured TVGN earnings events.
Where these TVGN earnings landedvs 21 measured TVGN earnings reactions
| Middle 50% of TVGN earnings reactions | -4.32% to +0.15% |
|---|---|
| Median reaction (to close) | -1.80% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 TVGN earnings events with a measured close landed between -4.32% and +0.15%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Tevogen Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -1.20% | |
| Form 10-Q Tevogen Bio Holdings For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +8.29% | |
| Form 10-K/A Tevogen Bio Holdings For: Dec 31 | SEC filing · Form 10-K | +0.38% | -3.06% | |
| Form 10-K Tevogen Bio Holdings For: Dec 31 | SEC filing · Form 10-K | +2.69% | +0.45% | |
| Form 10-Q Tevogen Bio Holdings For: Sep 30 | SEC filing · Form 10-Q | -0.80% | -2.48% | |
| Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q | Press release | +0.45% | -1.95% | |
| Form 10-Q Tevogen Bio Holdings For: Jun 30 | SEC filing · Form 10-Q | -0.78% | -2.24% | |
| Form 10-Q Tevogen Bio Holdings For: Mar 31 | SEC filing · Form 10-Q | +0.92% | +5.50% | |
| Form 10-K Tevogen Bio Holdings For: Dec 31 | SEC filing · Form 10-K | -0.47% | -4.76% | |
| Form NT 10-K Tevogen Bio Holdings For: Dec 31 | SEC filing · Form NT | -0.45% | -1.80% | |
| Form 10-Q Tevogen Bio Holdings For: Sep 30 | SEC filing · Form 10-Q | -3.33% | -13.94% | |
| Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model | Press release | -3.33% | -13.94% | |
| Form NT 10-Q Tevogen Bio Holdings For: Sep 30 | SEC filing · Form NT | +2.16% | -4.32% | |
| CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares | Press release | — | +1.44% | |
| Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares | Press release | -0.82% | +0.15% | |
| Form 10-Q Tevogen Bio Holdings For: Jun 30 | SEC filing · Form 10-Q | -0.82% | +0.15% | |
| Tevogen Bio Reports First Quarter 2024 Financial Results | Press release | +0.01% | -0.38% | |
| Form 10-Q Tevogen Bio Holdings For: Mar 31 | SEC filing · Form 10-Q | +0.01% | -0.38% | |
| Form NT 10-Q Tevogen Bio Holdings For: Mar 31 | SEC filing · Form NT | -2.27% | -6.82% | |
| Form 10-K Tevogen Bio Holdings For: Dec 31 | SEC filing · Form 10-K | -3.09% | +2.00% | |
| Form NT 10-K Tevogen Bio Holdings For: Dec 31 | SEC filing · Form NT | -1.34% | -12.38% |
Keep exploring
More TVGN: analyst actions → · SEC filings → · TVGN overview →